Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/4/2026, 12:00:00 AM
Announced a strategic collaboration with Inceptive Nucleics on June 4, 2026, to use AI in the discovery of RNAi therapies. The deal is valued at up to $2 billion, including a $30 million upfront payment, and the stock rose approximately 4%.
Korean Translation
2026년 6월 4일 RNAi 치료제 발견에 AI를 활용하기 위해 인셉티브 뉴클레익스와의 전략적 제휴를 발표함. 해당 계약은 3,000만 달러의 선급금을 포함하여 최대 20억 달러 규모이며, 주가는 약 4% 상승함.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM